Literature DB >> 17804687

Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo.

Silvia Bozza1, Roberta Gaziano, Pierluigi Bonifazi, Teresa Zelante, Lucia Pitzurra, Claudia Montagnoli, Silvia Moretti, Roberto Castronari, Paola Sinibaldi, Guido Rasi, Enrico Garaci, Francesco Bistoni, Luigina Romani.   

Abstract

Reactivation of latent human cytomegalovirus following allogeneic transplantation is a major cause of morbidity and mortality and predisposes to severe complications. Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, is approved for treatment of some viral infections and as an immune adjuvant. Talpha1 successfully primed dendritic cells (DCs) for anti-microbial T helper type 1 resistance through Toll-like receptor (TLR) 9 signaling. We sought to determine here whether Talpha1 could play a role in murine cytomegalovirus infection (MCMV). To this purpose, susceptible, resistant and TLR-deficient mice were infected with MCMV, treated with Talpha1 and assessed for protection in term of microbiological and immunological parameters. Talpha1 protected susceptible and resistant mice from MCMV infection. The anti-viral effect of Talpha1 occurred through the activation of plasmacytoid DCs via the TLR9/myeloid differentiation primary response gene 88-dependent viral recognition sensing, leading to the activation of IFN regulatory factor 7 and the promotion of the IFN-alpha/IFN-gamma-dependent effector pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804687     DOI: 10.1093/intimm/dxm097

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

1.  Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.

Authors:  Arevik Mosoian; Avelino Teixeira; Colin S Burns; Leif E Sander; G Luca Gusella; Cijiang He; J Magarian Blander; Paul Klotman; Mary E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

2.  NMR structure of human thymosin alpha-1.

Authors:  Miguel-Angel Elizondo-Riojas; Steven M Chamow; Cynthia W Tuthill; David G Gorenstein; David E Volk
Journal:  Biochem Biophys Res Commun       Date:  2011-11-15       Impact factor: 3.575

3.  Proteomic analysis of Pichindé virus infection identifies differential expression of prothymosin-alpha.

Authors:  Gavin C Bowick; Kizhake V Soman; He Wang; Judith F Aronson; Bruce A Luxon; Lee O Lomas; David G Gorenstein; Norbert K Herzog
Journal:  J Biomed Biotechnol       Date:  2010-04-18

Review 4.  Damage-associated molecular patterns and their receptors in upper airway pathologies.

Authors:  Koen Van Crombruggen; Fenila Jacob; Nan Zhang; Claus Bachert
Journal:  Cell Mol Life Sci       Date:  2013-05-15       Impact factor: 9.261

5.  Plasmacytoid dendritic cells and the control of herpesvirus infections.

Authors:  Thomas Baranek; Nicolas Zucchini; Marc Dalod
Journal:  Viruses       Date:  2009-10-14       Impact factor: 5.048

Review 6.  Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application.

Authors:  Martina Severa; Jing Zhang; Elena Giacomini; Fabiana Rizzo; Marilena Paola Etna; Melania Cruciani; Enrico Garaci; Michael Chopp; Eliana Marina Coccia
Journal:  Mult Scler Relat Disord       Date:  2018-10-02       Impact factor: 4.339

Review 7.  Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin.

Authors:  Claudio Costantini; Frank L van de Veerdonk; Luigina Romani
Journal:  Vaccines (Basel)       Date:  2020-12-01

8.  The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.

Authors:  Jianfeng Wu; Lixin Zhou; Jiyun Liu; Gang Ma; Qiuye Kou; Zhijie He; Juan Chen; Bin Ou-Yang; Minying Chen; Yinan Li; Xiaoqin Wu; Baochun Gu; Lei Chen; Zijun Zou; Xinhua Qiang; Yuanyuan Chen; Aihua Lin; Guanrong Zhang; Xiangdong Guan
Journal:  Crit Care       Date:  2013-01-17       Impact factor: 9.097

9.  Thymosin α1 treatment reduces hepatic inflammation and inhibits hepatocyte apoptosis in rats with acute liver failure.

Authors:  Xueliang Yang; Yunru Chen; Jian Zhang; Tiantian Tang; Ying Kong; Feng Ye; Xi Zhang; Xiaojing Liu; Shumei Lin
Journal:  Exp Ther Med       Date:  2018-02-07       Impact factor: 2.447

10.  Thymosin α1 protects from CTLA-4 intestinal immunopathology.

Authors:  Giorgia Renga; Marina M Bellet; Marilena Pariano; Marco Gargaro; Claudia Stincardini; Fiorella D'Onofrio; Paolo Mosci; Stefano Brancorsini; Andrea Bartoli; Allan L Goldstein; Enrico Garaci; Luigina Romani; Claudio Costantini
Journal:  Life Sci Alliance       Date:  2020-08-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.